Literature DB >> 22720220

Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer.

Maria Pia Protti1, Lucia De Monte.   

Abstract

Th2-type inflammation has been proposed to facilitate tumor growth. In De Monte et al. (J Exp Med 208:469-478, 2011) we identify in pancreatic cancer a complex cytokine/chemokine cross-talk within the tumor microenvironment mediating Th2 immune-deviation and show that the ratio of Th2/Th1 tumor infiltrating lymphocytes is an independent predictive marker of patients survival.

Entities:  

Year:  2012        PMID： 22720220      PMCID： PMC3376960          DOI： 10.4161/onci.1.1.17939

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

Review 2.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

3.  Thymic stromal lymphopoietin is a key mediator of breast cancer progression.

Authors:  Purevdorj B Olkhanud; Yrina Rochman; Monica Bodogai; Enkhzol Malchinkhuu; Katarzyna Wejksza; Mai Xu; Ronald E Gress; Charles Hesdorffer; Warren J Leonard; Arya Biragyn
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

Review 4.  TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation.

Authors:  Yong-Jun Liu; Vasilli Soumelis; Norihiko Watanabe; Tomoki Ito; Yui-Hsi Wang; Rene de Waal Malefyt; Miyuki Omori; Baohua Zhou; Steven F Ziegler
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

5.  Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients.

Authors:  Elena Tassi; Francesca Gavazzi; Luca Albarello; Vladimir Senyukov; Renato Longhi; Paolo Dellabona; Claudio Doglioni; Marco Braga; Valerio Di Carlo; Maria Pia Protti
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

Review 6.  Therapy directed against thymic stromal lymphopoietin.

Authors:  Matthew J Edwards
Journal:  Drug News Perspect       Date:  2008 Jul-Aug

Review 7.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

8.  Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.

Authors:  Lucia De Monte; Michele Reni; Elena Tassi; Daniela Clavenna; Ilenia Papa; Helios Recalde; Marco Braga; Valerio Di Carlo; Claudio Doglioni; Maria Pia Protti
Journal:  J Exp Med       Date:  2011-02-21       Impact factor: 14.307

9.  Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation.

Authors:  Alexander Pedroza-Gonzalez; Kangling Xu; Te-Chia Wu; Caroline Aspord; Sasha Tindle; Florentina Marches; Michael Gallegos; Elizabeth C Burton; Daniel Savino; Toshiyuki Hori; Yuetsu Tanaka; Sandra Zurawski; Gerard Zurawski; Laura Bover; Yong-Jun Liu; Jacques Banchereau; A Karolina Palucka
Journal:  J Exp Med       Date:  2011-02-21       Impact factor: 14.307

10.  Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients.

Authors:  Elena Tassi; Marco Braga; Renato Longhi; Francesca Gavazzi; Giorgio Parmiani; Valerio Di Carlo; Maria Pia Protti
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240
  10 in total
  22 in total

Review 1.  The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.

Authors:  Miles Piper; Adam C Mueller; Sana D Karam
Journal:  Mol Carcinog       Date:  2020-05-04       Impact factor: 4.784

2.  Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis.

Authors:  Noemi Eiro; Lucía González; Anxo Martínez-Ordoñez; Belen Fernandez-Garcia; Luis O González; Sandra Cid; Francisco Dominguez; Román Perez-Fernandez; Francisco J Vizoso
Journal:  Cell Oncol (Dordr)       Date:  2018-03-01       Impact factor: 6.730

Review 3.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

Review 4.  Nanomaterials for cancer immunotherapy.

Authors:  Wantong Song; Sara N Musetti; Leaf Huang
Journal:  Biomaterials       Date:  2017-09-17       Impact factor: 12.479

Review 5.  Cancer-associated fibroblasts as targets for immunotherapy.

Authors:  Sunitha Kakarla; Xiao-Tong Song; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2012-11       Impact factor: 4.196

6.  Crucial biological functions of CCL7 in cancer.

Authors:  Yangyang Liu; Yadi Cai; Li Liu; Yudong Wu; Xiangyang Xiong
Journal:  PeerJ       Date:  2018-06-14       Impact factor: 2.984

7.  Tumors induce de novo steroid biosynthesis in T cells to evade immunity.

Authors:  Bidesh Mahata; Jhuma Pramanik; Louise van der Weyden; Krzysztof Polanski; Gozde Kar; Angela Riedel; Xi Chen; Nuno A Fonseca; Kousik Kundu; Lia S Campos; Edward Ryder; Graham Duddy; Izabela Walczak; Klaus Okkenhaug; David J Adams; Jacqueline D Shields; Sarah A Teichmann
Journal:  Nat Commun       Date:  2020-07-17       Impact factor: 14.919

8.  The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer.

Authors:  Emanuela Brunetto; Lucia De Monte; Gianpaolo Balzano; Barbara Camisa; Vincenzo Laino; Michela Riba; Silvia Heltai; Marco Bianchi; Claudio Bordignon; Massimo Falconi; Attilio Bondanza; Claudio Doglioni; Maria Pia Protti
Journal:  J Immunother Cancer       Date:  2019-02-13       Impact factor: 13.751

9.  Mycobacterium bovis BCG promotes tumor cell survival from tumor necrosis factor-α-induced apoptosis.

Authors:  Sahana Holla; Devram Sampat Ghorpade; Vikas Singh; Kushagra Bansal; Kithiganahalli Narayanaswamy Balaji
Journal:  Mol Cancer       Date:  2014-09-11       Impact factor: 27.401

10.  Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq.

Authors:  Hongkai Zhuang; Xinming Chen; Ying Wang; Shanzhou Huang; Bo Chen; Chuanzhao Zhang; Baohua Hou
Journal:  Cancer Immunol Immunother       Date:  2021-07-19       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.